Preferred Label : Anti-HER2 Antibody-drug Conjugate JSKN003;
NCIt synonyms : Anti-HER2 ADC JSKN003; ADC JSKN003;
NCIt definition : An antibody-drug conjugate (ADC) composed of the bispecific monoclonal antibody anbenitamab,
directed against two distinct epitopes of the extracellular dimerization domain of
the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth
factor receptor 2 (HER2; ErbB2; HER-2), site-specifically conjugated via N glycosylation
site to a topoisomerase-1 inhibitor, with potential antineoplastic activity. Upon
administration of anti-HER2 ADC JSKN003, the anbenitamab moiety simultaneously targets
and binds to two separate, non-overlapping epitopes of HER2 expressed on tumor cells.
Upon binding and internalization, the topoisomerase-1 inhibitor moiety is released,
binds to topoisomerase-1 and stabilizes cleaved DNA-topoisomerase-1 complexes. This
prevents DNA re-ligation, induces irreversible DNA strand breaks, prevents DNA repair,
and leads to cycle arrest and apoptosis specifically in tumor cells expressing HER2.
HER2, a receptor tyrosine kinase that is mutated or overexpressed in many tumor cell
types, plays an important role in tumor cell proliferation and tumor vascularization.;
Molecule name : JSKN-003; JSKN 003;
NCI Metathesaurus CUI : CL1798744;
Origin ID : C190145;
UMLS CUI : C5783522;
Semantic type(s)
- concept_is_in_subset
